Compare Ecolab Inc. (ECL) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Incyte Corporation — how do they compare? Ecolab Inc. trades at $273.17 (market cap $76.06B), while Incyte Corporation trades at $116.08 (market cap $22.99B). The key difference: Ecolab Inc. is far larger — about 3.3× Incyte Corporation's market cap, and Ecolab Inc. pays a 1.08% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| ECL | INCY | |
|---|---|---|
Market Cap | $76.06B | $22.99B |
Sector | Consumer Cyclical | Health |
52-Week High | $308.35 | $118.52 |
52-Week Low | $245.73 | $67.38 |
Enterprise Value | $84.81B | $19.01B |
Dividend Yield | 1.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $273.62, up 1.43% with a bearish technical signal despite strong analyst support. The company shows solid fundamentals with $16.08B revenue, 12.8% net margin, and 22.31% ROE. Recent Q1 2026 earnings met expectations while Q2 2026 results are pending. The $4.75B CoolIT acquisition strengthens AI cooling capabilities, positioning for long-term growth in high-tech markets.
ECL presents a compelling growth story with improving profitability and strategic acquisitions, though current valuation multiples appear elevated. Key risks include execution of recent acquisitions and rising cost pressures. With 76% analyst buy ratings and a $327.43 consensus target suggesting 20% upside, the stock offers potential for patient investors despite near-term technical weakness.
INCY trades at $115.83, up 0.83% today, with a bullish technical signal from moving averages and strong fundamental performance including 2025 revenue of $5.14B and net income of $1.29B. Recent developments include positive Phase 1/2 data for VGA039 presented at ISTH 2026 and the acquisition of Vega Therapeutics, expanding its hematology portfolio. The stock shows robust profitability with a 26.71% net income margin and 30.82% ROE, while analyst consensus is a Buy with a $112.78 price target.
Outlook remains positive driven by pipeline advancements and earnings growth, though risks include clinical trial outcomes and regulatory hurdles. The current price above the consensus target suggests limited near-term upside, but continued execution could support further gains. Investors should weigh strong cash flow generation against competitive pressures in the biopharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
